Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01780662)
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin (also known SGN-035) as when given together with gemcitabine hydrochloride and to see how well they work in treating younger patients with Hodgkin lymphoma that has returned or does not respond to treatment.
Monoclonal antibody-drug conjugates such as brentuximab vedotin, may find cancer cells and help kill them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
It is expected that giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer cells.
This trial is sponsored by the National Cancer Institute (NCI).
- Condition: Hodgkin Lymphoma
- Drugs used in this trial
- Phase: I & II
- Estimated Enrollment: 72
- Start: January 2013
- Estimated Primary Completion: October 2015 (Final data collection date for primary outcome measure)
- Last verified: March 2015
Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.